Field notes on life sciences, biotech, and the people moving the industry forward. Written for the operators, not the headlines.
Get a free quarterly briefing: four pages on what life-sciences operators are actually saying about Biosecure, AI hype vs. substance, and the $50,000 cell-therapy question. Ten minutes, in your inbox.